CoreCap Advisors LLC Purchases 125 Shares of Zoetis Inc. (NYSE:ZTS)

CoreCap Advisors LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 13.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,050 shares of the company’s stock after acquiring an additional 125 shares during the period. CoreCap Advisors LLC’s holdings in Zoetis were worth $171,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Geode Capital Management LLC increased its holdings in Zoetis by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after buying an additional 190,137 shares during the last quarter. Polen Capital Management LLC raised its position in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Wellington Management Group LLP raised its position in Zoetis by 78.5% in the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock worth $1,047,052,000 after acquiring an additional 755,893 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Stifel Nicolaus lowered their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Finally, Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $161.68 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market cap of $72.14 billion, a PE ratio of 29.56, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The firm’s 50 day simple moving average is $157.17 and its 200-day simple moving average is $165.83. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis’s revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.38 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.